Literature DB >> 30474109

Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.

Daria R Bulanova1, Mikko Helenius1, Anna P Sokolenko2,3, Sergey G Kuznetsov1, Evgeny N Imyanitov2,3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30474109     DOI： 10.1002/ijc.32013

Source DB:  PubMed          Journal:  Int J Cancer        ISSN： 0020-7136            Impact factor:   7.396


× No keyword cloud information.
  2 in total

1.  Identification of immune-enhanced molecular subtype associated with BRCA1 mutations, immune checkpoints and clinical outcome in ovarian carcinoma.

Authors:  Mingjun Zheng; Yuexin Hu; Rui Gou; Ouxuan Liu; Xin Nie; Xiao Li; Qing Liu; Yingying Hao; Juanjuan Liu; Bei Lin
Journal:  J Cell Mol Med       Date:  2020-01-29       Impact factor: 5.310

2.  Identification of metabolism-associated molecular subtype in ovarian cancer.

Authors:  Xiaona Liu; Aoshen Wu; Xing Wang; Yunhe Liu; Yiang Xu; Gang Liu; Lei Liu
Journal:  J Cell Mol Med       Date:  2021-09-15       Impact factor: 5.310
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.